pyridoxine (vitamin B 6 ) in the circulation and tissues, is a coenzyme for over 100 enzymatic reactions including decarboxylation and transamination (1). PLP serves multiple functions and is a necessary nutrient for body growth, development, and overall health (1-3). Low vitamin B 6 status results in impaired glucose, lipid, and amino acid metabolism and is also associated with some pathological conditions and cancers (1). Patients with breast (4), colon (5, 6), bladder (7), or laryngeal (8) cancers and or Hodgkin's disease (1) have lower plasma PLP levels compared with healthy controls. In vitro studies have shown that pharmacological doses of vitamin B 6 (from 0.25-5 mm) inhibit cell proliferation and protein synthesis in HepG2 human hepatoma cells (9), human malignant melanoma (10, 11), and human lymphocytes (12). Mice pretreated with pyridoxal followed by injection of B16 melanoma cells had a 62% reduction in tumor weight compared with controls (11). These results suggest that vitamin B 6 may have potential use as an antineoplastic agent.
P YRIDOXAL PHOSPHATE (PLP), a bioactive form of
pyridoxine (vitamin B 6 ) in the circulation and tissues, is a coenzyme for over 100 enzymatic reactions including decarboxylation and transamination (1) . PLP serves multiple functions and is a necessary nutrient for body growth, development, and overall health (1) (2) (3) . Low vitamin B 6 status results in impaired glucose, lipid, and amino acid metabolism and is also associated with some pathological conditions and cancers (1) . Patients with breast (4), colon (5, 6) , bladder (7), or laryngeal (8) cancers and or Hodgkin's disease (1) have lower plasma PLP levels compared with healthy controls. In vitro studies have shown that pharmacological doses of vitamin B 6 (from 0.25-5 mm) inhibit cell proliferation and protein synthesis in HepG2 human hepatoma cells (9) , human malignant melanoma (10, 11) , and human lymphocytes (12) . Mice pretreated with pyridoxal followed by injection of B16 melanoma cells had a 62% reduction in tumor weight compared with controls (11) . These results suggest that vitamin B 6 may have potential use as an antineoplastic agent.
Administration of vitamin B 6 (either 300 mg acute infusion or 400 -600 mg orally daily for 2-3 months) to human volunteers (13) (14) (15) (16) reduced circulating prolactin (PRL) levels (13, 14, 16) , but PLP-induced GH reduction was observed only in acromegaly (14) and in infants (15) . Vitamin B 6 -induced hormone suppression was not reproduced in other in vivo studies (17, 18) .
Mechanisms for the observed inhibition of cell proliferation and alteration of hormone secretion by vitamin B 6 are unclear. We present results from in vitro studies showing that pharmacological levels of PLP inhibit rodent pituitary cell growth and hormone secretion, mediated in part through apoptosis.
Materials and Methods

Cell cultures
Normal rat pituitary tissues were obtained from adult Sprague Dawley rats, following the guidelines of the Institutional Animal Care and Use Committee. Pituitary cells were prepared as described (19, 20) . Briefly, pituitary tissue was minced and dissociated with 0.35% collagenase (Sigma Chemical Co., St. Louis, MO) and 0.15% hyaluronidase (Sigma) at 37 C for 45 min, followed by adding fetal bovine serum (FBS) (Life Technologies, Inc., Grand Island, NY) to neutralize enzymes. Rat pituitary cells were collected by centrifugation and incubated in DMEM (Life Technologies) containing 10% FBS. GH3 and MMQ rat pituitary cells and mouse AtT-20 pituitary cells were purchased from American Type Culture Collection (Rockville, MD). GH3 cells and MMQ cells were maintained in RPMI 1640 medium (Life Technologies) containing 15% house serum and 2.5% FBS. AtT-20 cells were maintained in DMEM with 10% FBS.
Pituitary cells were preincubated in maintenance medium for 48 -72 h and starved in phenol-free RPMI 1640 medium with 0.3% BSA (Sigma) for 6 -12 h, followed by PLP (Sigma) treatments with varying doses for the times indicated. Stock solutions of PLP (200 mm) were prepared in 1 n HCl. The highest dose (1 mm) of PLP was prepared by dilution of stock with phenol-free RPMI 1640 medium with 2.5% FBS, in which the final concentration was 0.005 n HCl. Lower doses of PLP were prepared by additional dilution of the highest-dose solution with phenol-free RPMI 1640 medium with 2.5% FBS and 0.005 n HCl. Vehicle controls were treated with medium containing 0.005 n HCl. Technologies). Cell number was measured using a Coulter Counter (Beckman Coulter, Miami, FL). For recovery studies, cells were pretreated with PLP for 4 d and then reexposed to maintenance medium without PLP. At the end of the experiments, cells were collected and counted.
Alternatively, cells were treated with PLP in six-well culture plates for 80 h and then exposed to 0. 
Hormone assay
GH and PRL concentrations in culture media were measured by RIA using immunoreagents provided by the National Hormone and Peptide Program (Dr. Parlow, Harbor-UCLA Medical Center, Torrance, CA). GH and PRL were iodinated using the iodogen method (21) . ACTH concentrations in AtT-20 cell culture medium were measured using a commercial RIA kit (ICN Diagnostics Inc., Costa Mesa, CA).
Cell-cycle analysis
Cells were treated with different doses of PLP in six-well plates or 100-ϫ 20-mm dishes for 96 h. After trypsinization, 10 6 cells were washed with 1ϫ PBS buffer (Life Technologies), fixed in 3 ml 70% methanol, washed with staining buffer, and resuspended in the staining buffer with 50 g/ml RNAse A (Sigma) and 50 g/ml propidium iodide. Cell-cycle analysis was performed using fluorescence-activated cell sorting.
Apoptosis analysis
Cells were treated with or without 1 mm PLP in six-well culture plates for 72 h. Apoptosis was assessed using the annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit I (BD Biosciences PharMingen, San Diego, CA). After trypsinization, cells were washed twice with PBS, suspended in binding buffer, and stained with annexin V-FITC and propidium iodide. Cells undergoing apoptosis were detected by flow cytometry.
Western blotting
After 48 h PLP treatment, cells were lysed in lysis buffer (Cell Signaling, Beverly, MA) containing 20 mm Tris-HCL, 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton, 2.5 mm sodium pyrophosphate, 1 mm ␤-glycerophosphate, 1 mm Na 2 VO 4 , 1 g/ml leupeptin, and 1 mm phenylmethylsulfonyl fluoride. After centrifugation, cell protein in the supernatant was quantified by the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA), and equal amounts (35 g) were separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. Nonspecific binding was blocked with 5% nonfat milk and 0.1% Tween 20 in PBS (Sigma). Antibody against Bcl-2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), or actin (Sigma) was incubated overnight with membranes at 4 C. Protein bands were visualized using second antibody conjugated with horseradish peroxidase and the ECL detection kit (Amersham Biosciences, part of GE Healthcare, Piscataway, NJ).
Statistical analysis
Results are presented as mean Ϯ sem. Student's t test without (for two groups) or with (for multiple groups) Bonferroni correction was used to determine differences between groups. lower cell proliferation rates (Fig. 3) . Even when exposed to 1 mm PLP for 7 d, cell numbers were maintained, suggesting that this high dose of PLP is not toxic to cells. To further test this, recovery studies were performed. After 4 d of PLP (from 100-1000 m) treatments, GH3 or AtT-20 cells were incubated in maintenance medium without added PLP for 3-11 d. After withdrawal of PLP, cells regained their growth in a dose-and time-dependent manner (Fig. 4) . Cells exposed to higher doses (1000 m) of PLP required a longer time (9 -11 d) to totally recover to control levels; when exposed to 100 m PLP, they required only 3-6 d for growth recovery.
Results
PLP inhibits GH3, MMQ, and
Recovery of cell proliferation after PLP withdrawal
PLP inhibits hormone secretion
PLP dose-dependently inhibited hormone secretion in MMQ, GH3, and AtT-20 cells, which was also confirmed after adjusting for cell number (Fig. 5) . After 2 d of treatment, PLP (10 -1000 m) reduced PRL secretion per MMQ cell to 67-26% (P Ͻ 0.05) of vehicle-treated controls, respectively. PRL levels per GH3 cell were reduced to 75-40% (P Ͻ 0.05) of controls, respectively, within 2 d of PLP treatment (100 -1000 m). GH levels were suppressed to 53-31% (P Ͻ 0.05), respectively, by the same treatments. ACTH levels per AtT-20 cell were reduced to 56 -32% (P Ͻ 0.05) of controls, respectively, after 2 d of PLP treatment (200 -1000 m).
PLP also dose-dependently inhibited PRL secretion from rat primary pituitary cultures. As shown in Fig. 6 , 2 d of PLP treatment (1-1000 m) reduced PRL concentrations to 66, 48, 35, and 37% of controls (P Ͻ 0.05 for all), respectively. In contrast, GH levels were not affected by PLP treatment in this system (Fig. 6 ). Cell numbers in rat primary pituitary cultures were reduced to 82 Ϯ 9 and 59 Ϯ 6% (P Ͻ 0.05) of controls.
PLP arrests the G1/S-phase cell-cycle transition
Cell-cycle analysis from three independent experiments (Fig. 7) showed that 4 d of treatment with 1 mm PLP decreased the percentage of AtT-20 cells in S and G2-M phases (4.98 vs. control 12.50, P ϭ 0.0025; and 0.65 vs. 3.00, P ϭ 0.0025, respectively). Similar results were observed in GH3 cells (13 
The tendency of cell cycle arrest was also observed in two experiments of primary rat pituitary cell culture. PLP (10 m) treatment for 48 h decreased the cell population in S phase (from 15.52% for control to 8.34%) and increased cells in G0-G1 (from 84.06% for control to 91.66%).
PLP induces apoptosis in pituitary cells
Three days of treatment with 1 mm PLP increased the number of AtT-20 cells undergoing apoptosis (27.7 vs. 6.0% for control, P ϭ 0.05) as well as in GH3 cells (25.5 vs. 3.2% for control, P ϭ 0.005). As shown in Fig. 8 , increased apoptosis fraction was associated with decreased viable cell population after PLP treatment, suggesting that higher doses of PLP cause pituitary cell apoptosis. content was reduced from 100% (control) to 52% (10 m), 50% (100 m), and 22% (1000 m) (P Ͻ 0.05 for all) (Fig. 9) .
PLP reduces Bcl-2 content in pituitary cells
Discussion
This study demonstrates that pharmacological doses of pyridoxal phosphate, the biologically active form of vitamin B 6 , inhibits rodent pituitary tumor cell proliferation, consistent with literature reports of pyridoxine-induced antiproliferative effects on other tumor cells (4 -12) . This effect was not caused by necrosis or potential toxic action of pyridoxine at high doses, because cell numbers were not significantly changed at the end of 7 d of exposure to 1 mm PLP, and cell growth recovered to normal levels after PLP withdrawal. PLP-induced inhibitory effects may be mediated through cell-cycle arrest and apoptosis, as suggested by our observations that 1) PLP treatment decreases the fraction of cells in S and G2-M phases and increases G0-G1, 2) PLP increases the apoptotic population, and 3) PLP reduced content of the antiapoptosis gene Bcl-2.
In this in vitro study, however, we could not determine whether our observed effects were a result of direct or indirect actions of PLP. Vitamin B 6 actions may be mediated indirectly through regulation of steroid hormone action (22, 23) . Estrogeninduced gene expression was reduced by 30% under conditions of elevated intracellular vitamin B 6 concentrations and was enhanced by 85% in vitamin deficiency (3) . Estrogen induced increased incorporation of [ (24); pyridoxal (300 m), however, prevented estrogen-induced cell proliferation activity. Antiestrogens effectively inhibit cell growth and induce apoptosis in rat pituitary GH4 cells (25) .
Antiproliferative activation by pyridoxal was, however, also observed in estrogen-receptor-negative breast cancer cells, and expression of the estrogen-sensitive gene pS2 was not affected by pyridoxal treatment (24) , suggesting that vitamin-B 6 -mediated cell growth may also occur through a mechanism that appears to be steroid independent.
PLP-induced effects may also be indirectly mediated through one-carbon metabolism pathways. Low levels of vitamin B 6 , B 12 , and folate can impair one-carbon metabolism pathways, resulting in homocysteine accumulation, insufficient methyl groups for DNA methylation, and depletion of DNA synthesis and repair, which potentially promote carcinogenesis (26 -30) . Moreover, PLP is thought to be a potential precursor of sulfane sulfur, a highly reactive sulfur atom with a reduced oxidation state and antiproliferation activity (31) . PLP-induced anti-carcinogenesis may also be mediated in vivo through improving immune-function (1, 2, 32) as well as antiangiogenic effects (33, 34) .
This study also demonstrates that PLP inhibits GH and PRL secretion, which resulted not only from PLP-induced reduction of cell numbers but also reduction of hormone secretion from individual cells treated with PLP (Fig .5) . In primary rat pituitary cells, PLP treatment inhibited PRL but not GH secretion (Fig. 6 ), likely because of reduced negative feedback by IGF-I derived from fibroblasts. In primary rat pituitary cultures, proliferation of somatotrope and lactotrope cells ceases as fibroblast cells grow with culture time. Therefore, PLP appears to inhibit fibrocyte proliferation and reduce IGF-I secretion (our data, which is not presented, showed that IGF-I concentration in the culture media was reduced to 79 -70% of control by 0.5-10 m PLP treatment for 6 d, and cell number and IGF-I levels were significantly correlated), thus decreasing local negative-feedback effects on GH secretion (35) , resulting in maintenance of GH levels from primary somatotrope cells exposed to PLP. PLP may also inhibit IGF-I secretion from other sources such as somatotrope and GH3 cells (36) , but block of the autocrine negative feedback seems to not effect PLP-induced inhibition of GH secretion in GH3 cells. The observed inhibition of hormone secretion might also be attributed to PLP-induced pituitary cell apoptosis.
Reports on effects of PLP on PRL and GH secretion in vivo have been contradictory (13) (14) (15) (16) (17) (18) . Vitamin B 6 may act on neural function in vivo through its involvement as a cofactor for dopamine. The effect of vitamin B 6 on circulating PRL and GH concentrations in human subjects were thought to be a result of increased dopaminergic activity (37, 38) . l-Dopa-or levodopa-induced alteration of GH and PRL secretion in vivo were affected by pyridoxine infusion (39, 40) , and the effect of iv administration of vitamin B 6 on circulating levels of human pituitary hormones was abolished by pretreatment with sulpiride, a dopamine receptor antagonist (41) . The reasons for the diverse responses to PLP observed in vivo are not clear but may be a result of different study designs and small sample sizes.
Pharmacological doses of PLP used to inhibit cell proliferation in our study in vitro (0.01-1 mm) and in reported references (0.25-5 mm) (9 -12) are likely not achieved in vivo (42, 43) . Human plasma PLP levels increased 6-fold (0.5 m) after administration of 100 mg pyridoxine-HCl per day (50 -100 times recommended dose) orally for 1-3 wk (42) but were not significantly additionally elevated by excess dietary pyridoxine (43) . Plasma PLP represents the major vitamin B 6 available to tissues, because the inactive pyridoxine form can convert to PLP in some tissues (1) . There are reports of several subjects who received 2-4 g pyridoxine per day (1000-to 4000-fold recommended supplement dose) for 2-48 months and developed severe sensory-nervous dysfunction (44, 45) , and this was considered a selective dorsal root ganglion toxicity (45) . PLP (0.5 m) did not show antiproliferation effects on human and murine cells in vitro (46) . But diets containing 4-to 10-fold the recommended pyridoxine did play roles in anti-cell proliferation in vivo (47, 48) . Dietary supplemental pyridoxine (7 or Ͼ7 mg/kg body weight) significantly reduced colon tumorigenesis and cell proliferation in mice receiving azoxymethane (47, 48) , and a high-fat diet markedly enhances a pyridoxine-induced inhibitory effect (49) . In human studies, there is an association between cancer incidence and lower plasma PLP levels (4 -8). These results suggest that pyridoxine doses required to inhibit tumor cell growth in vivo are much lower than those required in vitro.
Inhibitory effects of pyridoxine on cell proliferation in vivo may be mediated through multiple pathways as discussed above; therefore, smaller doses of pyridoxine in vivo may achieve similar effects as do large doses in vitro. In vivo experiments are required to test the effect of lower doses of PLP on pituitary tumor growth and hormone secretion, which may provide additional information about applying vitamin B 6 in clinic settings.
Thus, PLP is a potential anti-tumor-growth reagent and may serve as an adjunct drug in treatment of GH-and PRLsecreting adenoma growth and hormone secretion. PLP should also be considered as an added cocktail compound to potentiate available treatments for resistant pituitary adenomas. Optimal doses of pyridoxine applied clinically, however, remain to be determined.
